Abbott patents expiration
1. Hytrin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5294615 | ABBOTT | Terazosin polymorph and pharmaceutical composition |
Apr, 2013
(11 years ago) | |
| US5412095 | ABBOTT | Terazosin monohydrochloride and processes and intermediate for its production |
Apr, 2013
(11 years ago) | |
Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 07 August, 1987
Treatment: Treatment of symptomatic benign prostatic hyperplasia
Dosage: TABLET;ORAL; CAPSULE;ORAL
HYTRIN family patents
2. Meridia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5436272 | ABBOTT | Treatment of obesity |
Jul, 2012
(11 years ago) | |
|
US5436272 (Pediatric) | ABBOTT | Treatment of obesity |
Jan, 2013
(11 years ago) | |
Drugs and Companies using SIBUTRAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 November, 1997
Treatment: Treatment of obesity
Dosage: CAPSULE;ORAL
MERIDIA family patents
3. Norvir patents
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541206 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBOTT | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
|
US5541206 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBOTT | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5635523 | ABBOTT | Retroviral protease inhibiting compounds |
Jun, 2014
(9 years ago) | |
| US5648497 | ABBOTT | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5635523 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Dec, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBOTT | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 01 March, 1996
Treatment: Use of norvir to inhibit hiv protease or to inhibit an hiv infection; Use of ritonavir in combination with any reverse transcriptase inhibitor
Dosage: CAPSULE;ORAL
NORVIR family patents